Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: Where are we in 2003?

Inflammopharmacology

Volumn 11, Issue 4-6, 2003, Pages 337-354

  Yuan, Yuhong ^a   Hunt, Richard H ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Gastrointestinal safety; Non steroidal anti inflammatory drugs; Selective cyclooxygenase 2 inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; IBUPROFEN; INDOMETACIN; KETOPROFEN; LUMIRACOXIB; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PIROXICAM; ROFECOXIB; SULINDAC; THROMBOXANE; TOLMETIN; VALDECOXIB;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM ULCER; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; NEPHROTOXICITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; STOMACH DISEASE; STOMACH EROSION; STOMACH INJURY; THROMBOCYTE FUNCTION; THROMBOSIS;

EID: 0842284229     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856003322699528     Document Type: Conference Paper

References (108)

1. Agrawal, N., Paperiello, B. A., Zhao, W., et al. (2001). Supratherapeutic doses of valdecoxib have a reduced incidence of gastroduodenal ulcers compared with conventional therapeutic doses of naproxen in osteroarthritis and rheumatoid arthritis patients (abstract), Arthritis Rheum. 44 (Suppl. 1917), S372.
2. Alsalameh, S., Burian, M., Mahr, G., et al. (2003). Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor, Aliment. Pharmacol. Ther. 17, 489-501.
3. Bannwarth, B., Dorval, E., Caekaert, A., et al. (2002). Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal antiinflammatory drugs combined with omeprazole, J. Rheumatol. 29, 1975-1980.
4. Bayer Pharmaceuticals (2003). http://www.wonderdrug.com/press/factsheets/aspirin_fact_sheets/.pdf (accessed June 09, 2003).
5. Bianchi Porro, G., Parente, F., Imbesi, V., et al. (1996). Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy, Gut 39, 22-26.
6. Bombardier, C., Laine, L., Reicin, A., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group, N. Engl. J. Med. 343, 1520-1528.
7. Catella-Lawson, F., McAdam, B., Morrison, B. W., et al. (1999). Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids, J. Pharmacol. Exp. Ther. 289, 735-741.
8. Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., et al. (2001). Cyclooxygenase inhibitors and the antiplatelet effects of aspirin, N. Engl. J. Med. 345, 1809-1817.
9. Chan, F. K., Sung, J. J., Chung, S. C., et al. (1997). Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers, Lancet 350, 975-979.
10. Chan, F. K., Sung, J. J., Suen, R., et al. (1998). Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study, Aliment. Pharmacol. Ther. 12, 1201-1205.
11. Chan, F. K., Chung, S. C., Suen, B. Y., et al. (2001). Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J Med. 344, 967-973.
12. Chan, F. K., To, K. F., Wu, J. C., et al. (2002). Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 359, 9-13.
13. Crofford, L. J. (1997). COX-1 and COX-2 tissue expression: Implications and predictions, J. Rheumatol. 24 (Suppl. 49), 15-19.
14. Crofford, L. J., Lipsky, P. E., Brooks, P., et al. (2000). Basic biology and clinical application of specific cyclooxygenase-2 inhibitors, Arthritis Rheum. 43, 4-13.
15. Cryer, B. and Feldman, M. (1999). Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans, Gastroenterology 117, 17-25.
16. Davies, N. M. (1999). Sustained release and enteric coated NSAIDs: are they really GI safe?, J. Pharm. Pharm. Sci. 2, 5-14.
17. Dequeker, J., Hawkey, C., Kahan, A., et al. (1998). Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis, Br. J. Rheumatol. 37, 946-951.
18. Derry, S. and Loke, Y. K. (2000). Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis, Br. Med. J. 321, 1183-1187.
19. Ekenel, M., Avşar, E., İmeryüz, N., et al. (2003). Effects of selective COX-2 inhibitors on the gastric permeability of sucrose: a controlled study with placebo and ibuprofen, Eur. J. Gastroenterol. Hepatol. 15, 403-406.
20. El-Serag, H. B., Graham, D. Y., Richardson, P., et al. (2002). Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis, Arch. Intern. Med. 162, 2105-2110.
21. FDA (1998). Label for celecoxib, http://www.fda.gov/cder/foi/label/2002/20998s0091b1.pdf (accessed June 12, 2003).
22. FDA (2001a). FDA panel finds no safety benefit for celebrex, Scrip. World Pharm. News 2626, 19.
23. FDA (2001b). Throckmoron D, Memorandum. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_07.pdf (accessed July 07, 2003).
24. FDA (2001c). Targum L, Memorandum. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.doc (accessed July 07, 2003).
25. FDA (2002). FDA NDAC Meeting on Risks of NSAIDs on Sep 20, 2002, http://www.fda.gov/ohrms/dockets/ac/02/briefing/3882B2_04_Wyeth-Ibuprophen.pdf (accessed June 12, 2003).,
26. Fendrick, A. M. (2002). Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy, Clevel. Clin. J. Med. 69 (Suppl. 1), SI59-SI64.
27. Fisher, C., Boxkow, B., Crutis, S. P., et al. (2003). Result of a 190-week randomized study demonstrated similar efficacy of etoricoxib compared with diclofenac in patients with OA, Ann. Rheum. Dis. 62 (S 1), 273.
28. Gabriel, S. E., Jaakkimainen, L. and Bombardier, C. (1991). Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis, Ann. Intern. Med. 115, 787-796.
29. Garcia Rodriguez, L. A. and Jick, H. (1994). Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs, Lancet 343, 769-772.
30. Goldkind, L., Witter, J. and Lu, H. H. (2001). Statistical Reviewer Briefing Document for the Advisory Committee, http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_04_stats.pdf (accessed June 12, 2003).
31. Goldstein, J. L., Silverstein, F. E., Agrawal, N. M., et al. (2000). Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor, Am. J. Gastroenterol. 95, 1681-1690.
32. Goldstein, J. L., Talwalker, S., Verburg, K. M., et al. (2001). Comparative gastroduodenal mucosal of Valdecoxib, a potent COX-2 specific inhibitor, compared with naproxen and placebo, Gut 49 (Suppl. III), Abstract no. 2166.
33. Goldstein, J. L., Stenson, W. F., Agrawal, N., et al. (2002). Valdecoxib is associated with a significantly lower incidence of ulcer complications and symptomatic ulcers in arthritis patients as compared to NSAID, Gastroenterology 122 (Suppl. 1), A469 (abstract).
34. Graham, D. Y. (1996). Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand, Am. J. Gastroenterol. 91, 2080-2086.
35. Graham, D. Y. (2001). Helicobacterpylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications - future research needs, Am. J. Med. 110 (1A), 58S-61S.
36. Gutthann, S. P., Garcia Rodriguez L. A., et al. (1997). Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation, Epidemiology 8, 18-24
37. Harris, S. I., Kuss, M., Hubbard, R. C., et al. (2001). Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo, Clin. Ther. 23, 1422-1428.
38. Hawkey, C., Kahan, A., Steinbruck, K., et al. (1998a). Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment, Br. J. Rheumatol. 37, 937-945.
39. Hawkey, C. J., Karrasch, J. A., Szczepanski, L., et al. (1998b). Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group, N. Engl. J. Med. 338, 727-734.
40. Hawkey, C. J., Tulassay, Z., Szczepanski, L., et al. (1998c). Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention, Lancet 352, 1016-1021.
41. Hawkey, C. J. (1999). COX-2 inhibitors, Lancet 353, 307-314.
42. Hawkey, C., Laine, L., Simon, T., et al. (2000). Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial, Arthritis Rheum. 43, 370-377.
43. Hawkey, C. J., Laine, L., Harper, S. E., et al. (2001). Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials, Aliment. Pharmacol. Ther. 15, 1593-1601.
44. Hawkey, C. J., Karateev, D., Codreanu, C., et al. (2002). Improved upper gastrointestinal (UGI) safety and tolerability of a new COXIB, COX189, compared with ibuprofen in osteoarthritis patients, Ann. Rheum. Dis. 61 (Suppl. 1), 126 (abstract).
45. Hawkey, C. J., Laine, L. and Simon, T. (2003). Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomized, double blind study, Gut 52, 820-826.
46. Huang, J. Q., Sridhar, S. and Hunt, R. H. (1999). Gastrointestinal safety profile of nabumetone: a meta-analysis, Am. J. Med. 107, 55S-61S.
47. Huang, J. Q., Sridhar, S. and Hunt, R. H. (2002). Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis, Lancet 359, 14-22.
48. Hunt, R. H. (2003). Motion - cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments for the motion, Can. J. Gastroenterol. 17, 339-341.
49. Hunt, R. H., Bowen, B., Mortensen, E. R., et al. (2000). A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects, Am. J. Med. 109, 201-206.
50. Hunt, R. H., Barkun, A. N., Baron, D., et al. (2002). Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents, Can. J. Gastroenterol. 16, 231-240.
51. Hunt, R. H., Harper, S., Callegari, P., et al. (2003a). Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib, Aliment. Pharmacol. Ther. 17, 201-210.
52. Hunt, R. H., Harper, S., Watson, D. J., et al. (2003b). The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events, Am. J. Gastroenterol. 98, 1725-1733.
53. Kivitz, A., Eisen, G., Zhao, W. W., et al. (2002). Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis, J. Fam. Pract. 51, 530-537.
54. Koch, M., Dezi, A., et al. (1996). Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials, Arch. Intern. Med. 156, 2321-2332.
55. Konstam, M. A., Weir, M. R., Reicin, A., et al. (2001). Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib, Circulation 104, 2280-2288.
56. Konturek, P. C., Konturek, S. J., Czesnikiewicz, M., et al. (2002). Interaction of Helicobacter pylori (Hp) and nonsteroidal anti-inflammatory drugs (NSAID) on gastric mucosa and risk of ulcerations, Med. Sci. Monit. 8, RA197-RA209.
57. Kristiansen, I. S. and Kvien, K. T. (2002). Cost-effectiveness of replacing NSAIDs with coxibs: diclofenac and celecoxib in rheumatoid arthritis, Expert. Rev. Pharmacoec. Outcomes Res. 2, 229-241.
58. Labenz, J., Blum, A. L., Bolten, W. W., et al. (2002). Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial, Gut 51, 329-335.
59. Laine, L. (1996). Nonsteroidal anti-inflammatory drug gastropathy, Gastroint. Endosc. Clin. N. Am. 6, 489-504.
60. Laine, L. (2001). Approaches to NSAID use in the high-risk patient, Gastoenterology 120, 594-606.
61. Laine, L. (2003). Gastrointestinal effects of NSAIDs and Coxibs, J. Pain Symptom Manage. 25 (Suppl. 2), S32-S40.
62. Laine, L., Harper, S., Simon, T., et al. (1999). A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis, Gastroenterology 117, 776-783.
63. Laine, L., Bombardier, C., Hawkey, C. J., et al. (2002). Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis, Gastroenterology 123, 1006-1012.
64. Laine, L., Connors, L. G., Reicin, A., et al. (2003). Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use, Gastroenterology 124, 288-292.
65. Langman, M. J., Jensen, D. M., Watson, D. J., et al. (1999). Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs, J. Am. Med. Ass. 282, 1929-1933.
66. Lanza, F. L., Nelson, R. S. and Royer, G. L. (1979). Effects of ibuprofen, tolmetin and placebo on the gastric mucosa of aspirin-sensitive volunteers, Am. J. Gastroenterol. 72, 528-534.
67. Lanza, F. L. and the members of the Ad Hoc committee on practice parameters of the American College of Gastroenterology (1998). A guideline for the treatment and prevention of NSAID-induced ulcers, Am. J. Gastroenterol. 93, 2037-2045.
68. Lanza, F. L., Rack, M. F., Simon, T. J., et al. (1999). Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen, Aliment. Pharmacol. Ther. 13, 761-767.
69. Layton, D., Riley, J., Wilton, L. V., et al. (2003). Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study, Br. J. Clin. Pharmacol. 55, 166-174.
70. Leese, P. T., Talwalker, S., Kent, J. D., et al. (2002). Valdecoxib does not impair platelet function, Am. J. Emerg. Med. 20, 275-281.
71. MacDonald, T. M. and Wei, L. (2003). Effect of ibuprofen on cardioprotective effect of aspirin, Lancet 361, 573-574.
72. Maetzel, A. (2003). Motion - cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments against the motion, Can. J. Gastroenterol. 17, 335-338.
73. Marshall, J. K., Pellissier, J. M., Attard, C. L., et al. (2001). Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective, Pharmacoeconomics 19, 1039-1049.
74. Marshall, P. J., Berry, C. and Wasvary, J. (2002). The in vitro and in vivo selectivity of COX 189, a new and highly selective inhibitor of COX-2 (abstract), Ann. Rheum. Dis. 61 (Suppl. 1), 259.
75. McAdam, B. E., Catella-Lawson, E, Mardini, I. A., et al. (1999). Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2, Proc. Natl. Acad. Sci. USA 96, 272-277.
76. Moore, R. A. (2002). The hidden costs of arthritis treatment and the cost of new therapy - the burden of non-steroidal anti-inflammatory drug gastropathy, Rheumatology 41 (Suppl. 1), 7-15.
77. Mukherjee, D., Nissen, S. E. and Topol E. J. (2001). Risk of cardiovascular events associated with selective COX-2 inhibitors, J. Am. Med. Ass. 286, 954-959.
78. Ofman, J. J., MacLean, C. H., Straus, W. L., et al. (2002). A meta-analysis of severe upper gastrointestinal complications of nonsteroidal anti-inflammatory drugs, J. Rheumatol. 29, 804-812.
79. Rahme, E., Joseph, L., Kong, S. X., et al. (2000). Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population, Arthritis Rheum. 43, 917-924.
80. Ray, W. A., Stein, C. M., Hall, K., et al. (2002a). Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study, Lancet 359, 118-123.
81. Ray, W. A., Stein, C. M., Daugherty, J. R., et al. (2002b). COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease, Lancet 360, 1071-1073.
82. Riendeau, D., Percival, M. D., Brideau C., et al. (2001). Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2, J. Pharmacol. Exp. Ther. 296, 558-566.
83. Rordorf, C., Scott, G., Blood, P., et al. (2002). Treatment of healthy subjects with COX 189, a COX-2 selective inhibitor; endoscopic evidence for lack of gastro-duodenal erosions compared to non-selective NSAID (abstract), Ann. Rheum. Dis. 61 (Suppl. 1), 128.
84. Russell, R. I. (1999). Defining patients at risk of non-steroidal anti-inflammatory drug gastropathy, Ital. J. Gastroenterol. Hepatol. 31 (Suppl. 1), S14-S18.
85. Sanmuganathan, P. S., Ghahramani, P., Jackson, P. R., et al. (2001). Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials, Heart 85, 265-271.
86. Schoenfeld, P. (1999). Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials, Am. J. Med. 107 (6A), 48S-54S.
87. Sigthorsson, G., Crane, R., Simon, T., et al. (2000). COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin, Gut 47, 527-532.
88. Sikes, D. H., Agrawal, N. M., Zhao, W. W., et al. (2002). Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis, Eur. J. Gastroenterol. Hepatol. 14, 1101-1111.
89. Silverstein, F. E., Graham, D. Y., Senior, J. R., et al. (1995). Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial, Ann. Intern. Med. 123, 241-249.
90. Silverstein, F. E., Faich, G., Goldstein, J. L., et al. (2000). Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial, J. Am. Med. Ass. 284, 1247-1255.
91. Simon, L. S., Lanza, F. L., Lipsky, P. E., et al. (1998). Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects, Arthritis Rheum. 41, 1591-1602.
92. Simon, L. S., Weaver, A. L., Graham, D. Y., et al. (1999). Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial, J. Am. Med. Ass. 282, 1921-1928.
93. Singh, G. and Ramey, D. R. (1998). NSAID induced gastrointestinal complications: the ARAMIS perspective-1997, J. Rheumatol. 25 (Suppl. 51), 8-16.
94. Smalley, W. E., Ray, W. A., Daugherty, J. R., et al. (1995). Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons, Am. J. Epidemiol. 141, 539-545.
95. Sørensen, H. T., Mellemkjaer, L., Blot, W. J., et al. (2000). Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin, Am. J. Gastroenterol. 95, 2218-2224.
96. Spiegel, B. M., Targownik, L., Dulai, G. S., et al. (2003).The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis, Ann. Intern. Med. 138, 795-806.
97. Stack, W. A., Atherton, J. C., Hawkey, G. M., et al. (2002). Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding, Aliment. Pharmacol. Ther. 16, 497-506.
98. Stichtenoth, D. O. and Frölich, J. C. (2003). The second generation of COX-2 inhibitors: what advantages do the newest offer?, Drugs 63, 33-45.
99. Stoltz, R. R., Harris, S. I., Kuss, M. E., et al. (2002). Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects, Am. J. Gastroenterol. 97, 65-71.
100. Sung, J., Russell, R. I., Yeomans, N., et al. (2000). Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract, J. Gastroenterol. Hepatol. 15 (Suppl.), G58-G68.
101. Tacconelli, S., Capone, M. L., Sciulli, M. G., et al. (2002). The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity, Curr. Med. Res. Opin. 18, 503-511.
102. Talley, J. J., Brown, D. L., Carter, J. S., et al. (2000). 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2, J. Med. Chem. 43, 775-777.
103. Tramèr, M. R., Moore, R. A., Reynolds, D. J., et al. (2000). Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use, Pain 85, 169-182.
104. Van Hecken, A., Schwartz, J. I., Depre, M., et al. (2000). Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers, J. Clin. Pharmacol. 40, 1109-1120.
105. Watson, D. J., Rhodes, T., Cai, B., et al. (2002). Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis, Arch. Intern. Med. 162, 1105-1110.
106. Wolfe, M. M. (2003). Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs, Int. J. Clin. Pract. 135 (Suppl.), 32-37.
107. Wolfe, M. M., Lichtenstein, D. R. and Singh G. (1999). Gastrointestinal toxibity of nonsteroidal antiinflammatory drugs, N. Engl. J. Med. 340, 1888-1899.
108. Yeomans, N. D., Tulassay, Z., Juhasz, L., et al. (1998). A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group, N. Engl. J. Med. 338, 719-726.